Download PDF
Interventionelle Radiologie Scan 2016; 04(01): 69-86
DOI: 10.1055/s-0042-101580
Fortbildung
© Georg Thieme Verlag KG Stuttgart · New York

Irreversible Elektroporation – ein neues Therapieverfahren auf dem Prüfstand

Julian H. W. Jürgens
,
Uwe-Bernd Liehr
,
Johann J. Wendler
Further Information

Publication History

Publication Date:
10 March 2016 (online)

Also available at
    Permissions and Reprints
Fazit

Die IRE ist ein Ablationsverfahren, das aufgrund seiner molekularen, nonthermal-ablativen Wirkweise hohes Potenzial in der Tumortherapie besitzt. Im Menschen sollte es derzeit jedoch aufgrund des mangelnden Grundlagenverständnisses und der wenigen Belege für seine klinische Effektivität nur unter kontrollierten Studienbedingungen eingesetzt werden.

 

  • Literatur

  • 1 Doevenspeck H. Influencing cells and cell walls by electrostatic impulses. Fleischwirtschaft 1961; 13: 986-987
    Google Scholar
  • 2 Davalos RV, Mir IL, Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng 2005; 33: 223-231
    CrossrefPubMedGoogle Scholar
  • 3 Sugar IP, Neumann E. Stochastic model for electric field-induced membrane pores. Electroporation. Biophys Chem 1984; 19: 211-225
    CrossrefGoogle Scholar
  • 4 Lee EW, Wong D, Prikhodko SV et al. Electron microscopic demonstration and evaluation of irreversible electroporation-induced nanopores on hepatocyte membranes. J Vasc Interv Radiol 2012; 23: 107-113
    CrossrefGoogle Scholar
  • 5 Edd JF, Horowitz L, Davalos RV et al. In vivo results of a new focal tissue ablation technique: irreversible electroporation. IEEE Trans Biomed Eng 2006; 53: 1409-1415
    CrossrefGoogle Scholar
  • 6 Rubinsky B. Irreversible Electroporation. Berlin: Springer; 2010
    CrossrefGoogle Scholar
  • 7 Kosiek O, Strach K, Ricke J et al. Irreversible electroporation – a new kid on the block?. Radiologe 2012; 52: 38-43
    CrossrefGoogle Scholar
  • 8 Choi JW, Lu DS, Osuagwu F et al. Assessment of chronological effects of irreversible electroporation on hilar bile ducts in a porcine model. Cardiovasc Intervent Radiol 2014; 37: 224-230
    CrossrefGoogle Scholar
  • 9 Kasivisvanathan V, Shah TT, Donaldson I et al. Focal therapy for prostate cancer: German version. Urologe A 2015; 54: 202-209
    CrossrefGoogle Scholar
  • 10 Li W, Fan Q, Ji Z et al. The effects of irreversible electroporation (IRE) on nerves. PLoS One 2011; 6: e18831
    CrossrefGoogle Scholar
  • 11 Schoellnast H, Monette S, Ezell PC et al. Acute and subacute effects of irreversible electroporation on nerves: experimental study in a pig model. Radiology 2011; 260: 421-427
    CrossrefPubMedGoogle Scholar
  • 12 Schoellnast H, Monette S, Ezell PC et al. The delayed effects of irreversible electroporation ablation on nerves. Eur Radiol 2013; 23: 375-380
    CrossrefGoogle Scholar
  • 13 Wendler JJ, Pech M, Blaschke S et al. Angiography in the isolated perfused kidney: radiological evaluation of vascular protection in tissue ablation by nonthermal irreversible electroporation. Cardiovasc Intervent Radiol 2012; 35: 383-390
    CrossrefGoogle Scholar
  • 14 Wendler JJ, Pech M, Porsch M et al. Urinary tract effects after multifocal nonthermal irreversible electroporation of the kidney: acute and chronic monitoring by magnetic resonance imaging, intravenous urography and urinary cytology. Cardiovasc Intervent Radiol 2012; 35: 921-926
    CrossrefGoogle Scholar
  • 15 Wendler JJ, Porsch M, Huhne S et al. Short- and mid-term effects of irreversible electroporation on normal renal tissue: an animal model. Cardiovasc Intervent Radiol 2013; 36: 512-520
    CrossrefGoogle Scholar
  • 16 Nielsen K, Scheffer HJ, Vieveen JM et al. Anaesthetic management during open and percutaneous irreversible electroporation. Br J Anaesth 2014; 113: 985-992
    CrossrefGoogle Scholar
  • 17 Garcia PA, Rossmeisl Jr JH, Robertson JL et al. 7.0-T magnetic resonance imaging characterization of acute blood-brain-barrier disruption achieved with intracranial irreversible electroporation. PLoS One 2012; 7: e50482
    CrossrefGoogle Scholar
  • 18 Rossmeisl Jr JH, Garcia PA, Pancotto TE et al. Safety and feasibility of the NanoKnife system for irreversible electroporation ablative treatment of canine spontaneous intracranial gliomas. J Neurosurg 2015; 123: 1008-1025
    CrossrefGoogle Scholar
  • 19 Ball C, Thomson KR, Kavnoudias H. Irreversible electroporation: a new challenge in “out of operating theater” anesthesia. Anesth Analg 2010; 110: 1305-1309
    CrossrefPubMedGoogle Scholar
  • 20 Martin RC, Schwartz E, Adams J et al. Intra-operative anesthesia management in patients undergoing surgical irreversible electroporation of the pancreas, liver, kidney, and retroperitoneal tumors. Anesth Pain Med 2015; 5: e22786
    PubMedGoogle Scholar
  • 21 Arena CB, Sano MB, Rossmeisl Jr JH et al. High-frequency irreversible electroporation (H-FIRE) for non-thermal ablation without muscle contraction. Biomed Eng Online 2011; 10: 102
    CrossrefPubMedGoogle Scholar
  • 22 Deodhar A, Dickfeld T, Single GW et al. Irreversible electroporation near the heart: ventricular arrhythmias can be prevented with ECG synchronization. AJR Am J Roentgenol 2011; 196: W330-W335
    CrossrefGoogle Scholar
  • 23 Sugimoto K, Moriyasu F, Takeuchi H et al. Case study to assess the safety of irreversible electroporation near the heart. Springerplus 2015; 4: 74
    CrossrefGoogle Scholar
  • 24 Thomson KR, Cheung W, Ellis SJ et al. Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol 2011; 22: 611-621
    CrossrefGoogle Scholar
  • 25 Ricke J, Jurgens JH, Deschamps F et al. Irreversible electroporation (IRE) fails to demonstrate efficacy in a prospective multicenter phase II trial on lung malignancies: the ALICE trial. Cardiovasc Intervent Radiol 2015; 38: 401-408
    CrossrefPubMedGoogle Scholar
  • 26 Fredericks C, Arslan B, Mullane M et al. Needle tract seeding following irreversible electroporation (IRE) of metastatic colorectal carcinoma to the liver. Cardiovasc Intervent Radiol 2015; 38: 1349-1351
    CrossrefGoogle Scholar
  • 27 Liehr UB, Wendler JJ, Blaschke S et al. Irreversible electroporation: the new generation of local ablation techniques for renal cell carcinoma. Urologe A 2012; 51: 1728-1734
    CrossrefGoogle Scholar
  • 28 Xiao C, Rubinsky B. Theoretical analysis of AC electric field transmission into biological tissue through frozen saline for electroporation. Bioelectromagnetics 2014; 35: 607-613
    CrossrefGoogle Scholar
  • 29 Golberg A, Bruinsma BG, Uygun BE et al. Tissue heterogeneity in structure and conductivity contribute to cell survival during irreversible electroporation ablation by “electric field sinks”. Sci Rep 2015; 5: 8485
    CrossrefGoogle Scholar
  • 30 Neal RE, Kavnoudias H, Thomson KR. An “off-the-shelf” system for intraprocedural electrical current evaluation and monitoring of irreversible electroporation therapy. Cardiovasc Intervent Radiol 2015; 38: 736-741
    CrossrefGoogle Scholar
  • 31 Mansson C, Nilsson A, Karlson BM. Severe complications with irreversible electroporation of the pancreas in the presence of a metallic stent: a warning of a procedure that never should be performed. Acta Radiol Short Rep 2014; 3: 2047981614556409
    Google Scholar
  • 32 Faroja M, Ahmed M, Appelbaum L et al. Irreversible electroporation ablation: Is all the damage nonthermal?. Radiology 2013; 266: 462-470
    CrossrefPubMedGoogle Scholar
  • 33 van Gemert MJ, Wagstaff PG, de Bruin DM et al. Irreversible electroporation: just another form of thermal therapy?. Prostate 2015; 75: 332-335
    CrossrefGoogle Scholar
  • 34 Dunki-Jacobs EM, Philips P, Martin RC. Evaluation of thermal injury to liver, pancreas and kidney during irreversible electroporation in an in vivo experimental model. Br J Surg 2014; 101: 1113-1121
    CrossrefPubMedGoogle Scholar
  • 35 Davalos RV, Bhonsle S, Neal RE. Implications and considerations of thermal effects when applying irreversible electroporation tissue ablation therapy. Prostate 2015; 75: 1114-1118
    CrossrefGoogle Scholar
  • 36 Kluger MD, Epelboym I, Schrope BA et al. Single-institution experience with irreversible electroporation for T4 pancreatic cancer: first 50 patients. Ann Surg Oncol 2015; [Epub ahead of print]
    Google Scholar
  • 37 Little MW, Chung D, Boardman P et al. Microwave ablation of pulmonary malignancies using a novel high-energy antenna system. Cardiovasc Intervent Radiol 2013; 36: 460-465
    CrossrefGoogle Scholar
  • 38 Yan TD, King J, Sjarif A et al. Percutaneous radiofrequency ablation of pulmonary metastases from colorectal carcinoma: prognostic determinants for survival. Ann Surg Oncol 2006; 13: 1529-1537
    CrossrefGoogle Scholar
  • 39 Bilal H, Mahmood S, Rajashanker B et al. Is radiofrequency ablation more effective than stereotactic ablative radiotherapy in patients with early stage medically inoperable non-small cell lung cancer?. Interact Cardiovasc Thorac Surg 2012; 15: 258-265
    CrossrefGoogle Scholar
  • 40 Lee H, Jin GY, Han YM et al. Comparison of survival rate in primary non-small-cell lung cancer among elderly patients treated with radiofrequency ablation, surgery, or chemotherapy. Cardiovasc Intervent Radiol 2012; 35: 343-350
    CrossrefGoogle Scholar
  • 41 Usman M, Moore W, Talati R et al. Irreversible electroporation of lung neoplasm: a case series. Med Sci Monit 2012; 18: CS43-CS47
    CrossrefGoogle Scholar
  • 42 Scheffer HJ, Nielsen K, van Tilborg AA et al. Ablation of colorectal liver metastases by irreversible electroporation: results of the COLDFIRE-I ablate-and-resect study. Eur Radiol 2014; 24: 2467-2475
    CrossrefGoogle Scholar
  • 43 Niessen C, Igl J, Pregler B et al. Factors associated with short-term local recurrence of liver cancer after percutaneous ablation using irreversible electroporation: a prospective single-center study. J Vasc Interv Radiol 2015; 26: 694-702
    CrossrefGoogle Scholar
  • 44 Fritz S, Sommer CM, Vollherbst D et al. Irreversible electroporation of the pancreas is feasible and safe in a porcine survival model. Pancreas 2015; 44: 791-798
    CrossrefPubMedGoogle Scholar
  • 45 Trueba-Arguinarena FJ, de Prado-Otero DS, Poves-Alvarez R. Pancreatic adenocarcinoma treated with irreversible electroporation case report: first experience and outcome. Medicine (Baltimore) 2015; 94: e946
    CrossrefGoogle Scholar
  • 46 Moir J, White SA, French JJ et al. Systematic review of irreversible electroporation in the treatment of advanced pancreatic cancer. Eur J Surg Oncol 2014; 40: 1598-1604
    CrossrefGoogle Scholar
  • 47 Martin RC, McFarland K, Ellis S et al. Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma. J Am Coll Surg 2012; 215: 361-369
    CrossrefGoogle Scholar
  • 48 Seufferlein T, Bachet JB, Van CE et al. Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23: vii33-vii40
    Google Scholar
  • 49 Venkat S, Hosein PJ, Narayanan G. Percutaneous approach to irreversible electroporation of the pancreas: Miami protocol. Tech Vasc Interv Radiol 2015; 18: 153-158
    CrossrefPubMedGoogle Scholar
  • 50 Young SJ. Irreversible electroporation and the pancreas: What we know and where we are going?. World J Gastrointest Surg 2015; 7: 138-144
    CrossrefPubMedGoogle Scholar
  • 51 Ljungberg B, Bensalah K, Canfield S et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 2015; 67: 913-924
    CrossrefGoogle Scholar
  • 52 Pech M, Janitzky A, Wendler JJ et al. Irreversible electroporation of renal cell carcinoma: a first-in-man phase I clinical study. Cardiovasc Intervent Radiol 2011; 34: 132-138
    CrossrefGoogle Scholar
  • 53 Wendler JJ, Porsch M, Nitschke S et al. A prospective phase 2a pilot study investigating focal percutaneous irreversible electroporation (IRE) ablation by NanoKnife in patients with localised renal cell carcinoma (RCC) with delayed interval tumour resection (IRENE trial). Contemp Clin Trials 2015; 43: 10-19
    CrossrefGoogle Scholar
  • 54 Wendler JJ, Ricke J, Pech M et al. First delayed resection findings after irreversible electroporation (IRE) of human localised renal cell carcinoma (RCC) in the IRENE pilot phase 2a trial. Cardiovasc Intervent Radiol 2015; [Epub ahead of print]
    Google Scholar
  • 55 Rendon RA, Kachura JR, Sweet JM et al. The uncertainty of radio frequency treatment of renal cell carcinoma: findings at immediate and delayed nephrectomy. J Urol 2002; 167: 1587-1592
    CrossrefGoogle Scholar
  • 56 Klingler HC, Marberger M, Mauermann J et al. “Skipping” is still a problem with radiofrequency ablation of small renal tumours. BJU Int 2007; 99: 998-1001
    CrossrefGoogle Scholar
  • 57 Valerio M, Stricker PD, Ahmed HU et al. Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer. Prostate Cancer Prostatic Dis 2014; 17: 343-347
    CrossrefGoogle Scholar
  • 58 van den Bos W, de Bruin DM, van Randen A et al. MRI and contrast-enhanced ultrasound imaging for evaluation of focal irreversible electroporation treatment: results from a phase I–II study in patients undergoing IRE followed by radical prostatectomy. Eur Radiol 2015; [Epub ahead of print]
    Google Scholar
  • 59 van den Bos W, de Bruin DM, Jurhill RR et al. The correlation between the electrode configuration and histopathology of irreversible electroporation ablations in prostate cancer patients. World J Urol 2015; [Epub ahead of print]
    Google Scholar
  • 60 Tomihama RT, Günther E, Kim D et al. Irreversible electroporation treatment for prostate adenocarcinomas: a safety outcome study. J Vasc Intervent Radiol 2015; 26: 121-S122
    Google Scholar
  • 61 Neal RE, Smith RL, Kavnoudias H et al. The effects of metallic implants on electroporation therapies: feasibility of irreversible electroporation for brachytherapy salvage. Cardiovasc Intervent Radiol 2013; 36: 1638-1645
    CrossrefGoogle Scholar
  • 62 Qin Z, Jiang J, Long G et al. Irreversible electroporation: an in vivo study with dorsal skin fold chamber. Ann Biomed Eng 2013; 41: 619-629
    CrossrefGoogle Scholar
  • 63 Phillips MA, Narayan R, Padath T et al. Irreversible electroporation on the small intestine. Br J Cancer 2012; 106: 490-495
    CrossrefGoogle Scholar
  • 64 Schoellnast H, Monette S, Ezell PC et al. Irreversible electroporation adjacent to the rectum: evaluation of pathological effects in a pig model. Cardiovasc Intervent Radiol 2013; 36: 213-220
    CrossrefGoogle Scholar
  • 65 Srimathveeravalli G, Wimmer T, Monette S et al. Evaluation of an endorectal electrode for performing focused irreversible electroporation ablations in the Swine rectum. J Vasc Interv Radiol 2013; 24: 1249-1256
    CrossrefGoogle Scholar
  • 66 Niessen C, Jung EM, Beyer L et al. Percutaneous irreversible electroporation (IRE) of prostate cancer: contrast-enhanced ultrasound (CEUS) findings. Clin Hemorheol Microcirc 2015; 61: 135-141
    Google Scholar
  • 67 Ting F, Tran M, Bohm M et al. Focal irreversible electroporation for prostate cancer: functional outcomes and short-term oncological control. Prostate Cancer Prostatic Dis 2015; [Epub ahead of print]
    Google Scholar
  • 68 Wendler JJ, Fischbach K, Ricke J et al. Irreversible electroporation (IRE): standardization of terminology and reporting criteria for analysis and comparison. Pol J Radiol 2016; [in press, Feb 2016]
    Google Scholar